Infection, Human Immunodeficiency Virus I Clinical Trial
Official title:
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
| Verified date | April 2018 |
| Source | ViiV Healthcare |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
This study was designed to evaluate and compare safety, tolerability of subjects who successfully suppress HIV-1 on their first PI regimen to those who switch to fosamprenavir. This is a 48-week study, where subjects who were assigned to be in their original PI-group have the option of switching to fosamprenavir on week 24. Prior to being assigned their treatment group, subjects had to be suppressed for at least three months. All subjects also take a background regimen of two nucleoside/nucleotide reverse transcriptase inhibitors.
| Status | Completed |
| Enrollment | 314 |
| Est. completion date | June 29, 2007 |
| Est. primary completion date | June 29, 2007 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - Be on your first protease inhibitor (PI) containing regimen, and the regimen must consist of a PI +/- ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (N[t]RTIs). - Have a plasma HIV-1 RNA level (viral load) at screening of less than 400 copies/mL, for at least 3 months prior to Screening and at Screening while on your current regimen of a PI +/- ritonavir + 2 N(t)RTIs. - Females must not be pregnant or breastfeeding or plan to become pregnant during the study. - Females of child-bearing potential must agree to use one of the approved methods of birth control. Exclusion Criteria: - Not able to follow the medication schedules and attend the study visits for the entire length of the study. - Have any other illnesses, laboratory test results, medication use, allergies, or medical conditions that would make it unsafe for the subject to participate in this study. - Currently be enrolled in any other research studies that could affect the subject''''s HIV-1 RNA levels. |
| Country | Name | City | State |
|---|---|---|---|
| Puerto Rico | GSK Investigational Site | Ponce | |
| United States | GSK Investigational Site | Akron | Ohio |
| United States | GSK Investigational Site | Allentown | Pennsylvania |
| United States | GSK Investigational Site | Atlanta | Georgia |
| United States | GSK Investigational Site | Augusta | Georgia |
| United States | GSK Investigational Site | Beverly Hills | California |
| United States | GSK Investigational Site | Brooklyn | New York |
| United States | GSK Investigational Site | Charlotte | North Carolina |
| United States | GSK Investigational Site | Charlotte | North Carolina |
| United States | GSK Investigational Site | Columbia | South Carolina |
| United States | GSK Investigational Site | Dallas | Texas |
| United States | GSK Investigational Site | Dallas | Texas |
| United States | GSK Investigational Site | Denver | Colorado |
| United States | GSK Investigational Site | Des Moines | Iowa |
| United States | GSK Investigational Site | Detroit | Michigan |
| United States | GSK Investigational Site | Fort Collins | Colorado |
| United States | GSK Investigational Site | Fort Lauderdale | Florida |
| United States | GSK Investigational Site | Fort Lauderdale | Florida |
| United States | GSK Investigational Site | Fort Lauderdale | Florida |
| United States | GSK Investigational Site | Fort Myers | Florida |
| United States | GSK Investigational Site | Fort Worth | Texas |
| United States | GSK Investigational Site | Fresno | California |
| United States | GSK Investigational Site | Hampton | Virginia |
| United States | GSK Investigational Site | Hillsborough | New Jersey |
| United States | GSK Investigational Site | Houston | Texas |
| United States | GSK Investigational Site | Houston | Texas |
| United States | GSK Investigational Site | Jackson | Mississippi |
| United States | GSK Investigational Site | Jacksonville | Florida |
| United States | GSK Investigational Site | Laguna Beach | California |
| United States | GSK Investigational Site | Lexington | Kentucky |
| United States | GSK Investigational Site | Long Beach | California |
| United States | GSK Investigational Site | Longview | Texas |
| United States | GSK Investigational Site | Los Angeles | California |
| United States | GSK Investigational Site | Louisville | Kentucky |
| United States | GSK Investigational Site | Miami | Florida |
| United States | GSK Investigational Site | Morristown | Tennessee |
| United States | GSK Investigational Site | New Orleans | Louisiana |
| United States | GSK Investigational Site | New Orleans | Louisiana |
| United States | GSK Investigational Site | New York | New York |
| United States | GSK Investigational Site | Oklahoma City | Oklahoma |
| United States | GSK Investigational Site | Orlando | Florida |
| United States | GSK Investigational Site | Plantation | Florida |
| United States | GSK Investigational Site | Rochester | New York |
| United States | GSK Investigational Site | Shreveport | Louisiana |
| United States | GSK Investigational Site | Somers Point | New Jersey |
| United States | GSK Investigational Site | Tampa | Florida |
| United States | GSK Investigational Site | Tarzana | California |
| United States | GSK Investigational Site | Tulsa | Oklahoma |
| United States | GSK Investigational Site | Valhalla | New York |
| United States | GSK Investigational Site | Washington | District of Columbia |
| United States | GSK Investigational Site | West Palm Beach | Florida |
| United States | GSK Investigational Site | Wichita | Kansas |
| Lead Sponsor | Collaborator |
|---|---|
| ViiV Healthcare | GlaxoSmithKline |
United States, Puerto Rico,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Percentage of subjects with HIV-1 RNA less than 400 copies/mL | Week 24 | ||
| Secondary | Percentage of subjects with plasma HIV-1 RNA <400 copies/mL | Week 48 | ||
| Secondary | Percentage of subjects with plasma HIV-1 RNA <50 copies/mL at Week 24 | Week 24 | ||
| Secondary | Percentage of subjects with plasma HIV-1 RNA <50 copies/mL at Week 48 | Week 48 | ||
| Secondary | Number of subjects with any adverse events (AEs) | up to Week 48 | ||
| Secondary | Number of subjects with gastrointestinal (GI) AEs | up to Week 48 | ||
| Secondary | Absolute values of plasma HIV-1 RNA at Week 24 | Week 24 | ||
| Secondary | Median change from Baseline in HIV-1 RNA at Week 24 | Baseline and Week 24 | ||
| Secondary | Absolute values of plasma HIV-1 RNA at Week 48 | Week 48 | ||
| Secondary | Median change from Baseline in HIV-1 RNA at Week 48 | Baseline and Week 48 | ||
| Secondary | Absolute values in Cluster of Differentiation 4+ (CD4+) Cell Counts at Week 24 | Week 24 | ||
| Secondary | Absolute values in Cluster of Differentiation 4+ (CD4+) Cell Counts at Week 48 | Week 48 | ||
| Secondary | Median change from Baseline in Cluster of Differentiation 4+ (CD4+) Cell Counts at Week 24 | Baseline and Week 24 | ||
| Secondary | Median change from Baseline in Cluster of Differentiation 4+ (CD4+) Cell Counts at Week 48 | Baseline and Week 48 | ||
| Secondary | Number of subjects with genotypic resistance at virologic failure | up to Week 48 | ||
| Secondary | Number of subjects with phenotypic resistance at virologic failure | up to Week 48 | ||
| Secondary | Time to loss of virologic response (TLOVR) | up to Week 48 | ||
| Secondary | Medication adherence at Week 24 | Week 24 | ||
| Secondary | Medication adherence at Week 48 | Week 48 | ||
| Secondary | Subject treatment satisfaction per the HIV Treatment Satisfaction Questionnaire at Week 24 | Week 24 | ||
| Secondary | Subject treatment satisfaction per the HIV Treatment Satisfaction Questionnaire at Week 48 | Week 48 |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03327740 -
PRJ2203: Dolutegravir Post Authorization Safety Study (PASS)
|
||
| Completed |
NCT00257621 -
GW640385 Plus Ritonavir And NRTIs For 48 Weeks In HIV-1 Infected Adults
|
Phase 2 | |
| Completed |
NCT01227824 -
A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily
|
Phase 3 | |
| Completed |
NCT01597648 -
A Study to Evaluate the Bioequivalence of a Combined Formulated Tablet Compared With Maraviroc and Combivir™
|
Phase 1 | |
| Completed |
NCT01205243 -
ZIAGEN® Post-marketing Surveillance
|
||
| Withdrawn |
NCT01283100 -
A Drug Interaction Study Evaluating Plasma GSK2248761 and GSK1349572 Pharmacokinetics in Healthy Adult Subjects.
|
Phase 1 | |
| Completed |
NCT00440947 -
Induction/Simplification With Atazanavir + Ritonavir + Abacavir/Lamivudine Fixed-Dose Combination In HIV-1 Infection
|
Phase 3 | |
| Completed |
NCT00450580 -
HIV-1 Infection Study of Once a Day Versus Twice a Day Protease Inhibitor in Antiretroviral Treatment Naive Adults
|
Phase 3 | |
| Completed |
NCT00549198 -
KIVEXA Vs TRUVADA, Both Administered With Efavirenz, In ART-Naive Subjects
|
Phase 4 | |
| Completed |
NCT00481390 -
Prospective Epidemiological Study Of The Prevalence Of HLA-B*5701 In HIV-1 Infected Patients
|
N/A | |
| Completed |
NCT00242840 -
Observational Study Of A Protease Inhibitor (PI) Containing Regimen In Subjects With PI Mutations Selected During Prior Treatment With GW433908 (Fosamprenavir)
|
Phase 3 | |
| Terminated |
NCT00197145 -
Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5-Tropic Treatment-Experienced HIV-Infected Subjects
|
Phase 3 | |
| Completed |
NCT00089583 -
48-Week Study Of GW433908 And Ritonavir Or GW433908 Alone, Twice Daily In Pediatric Patients With HIV Infection
|
Phase 2 | |
| Completed |
NCT00044577 -
New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected Subjects
|
Phase 3 | |
| Terminated |
NCT00104429 -
GW873140 In Combination With Combivir In HIV Infected Subjects
|
Phase 2 | |
| Completed |
NCT01263015 -
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
|
Phase 3 | |
| Terminated |
NCT00102778 -
GW873140 In Combination With Kaletra In HIV Infected Subjects
|
Phase 2 | |
| Completed |
NCT00046176 -
A HIV Study Of A Fixed-Dose Combination Tablet In Antiretroviral Experienced Patients
|
Phase 3 | |
| Terminated |
NCT00242879 -
A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults
|
Phase 2 | |
| Completed |
NCT00082394 -
A Study Comparing The Safety, Tolerability and Efficacy of Trizivir VS Combivir & Atazanavir In Subjects With HIV
|
Phase 4 |